We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Innovative PCR Platform Delivers Sample-to-Result Molecular Testing Across All Laboratory Settings

By LabMedica International staff writers
Posted on 22 Dec 2023

A multiplex real-time PCR testing platform generates results in 25 minutes or less, improves clinical care, delivers cost savings, and offers sample-to-result molecular testing across all laboratory settings. More...

QuidelOrtho Corporation’s (San Diego, CA, USA) innovative Savanna PCR platform is a cutting-edge diagnostic tool that allows professional users to test for up to 12 pathogens or targets and up to four controls in a single run, delivering results in approximately 25 minutes, depending on the specific assay. Savanna is a fully integrated, sample-to-result, automated in vitro diagnostic system that carries out real-time polymerization chain reaction (PCR) testing using the Savanna instrument alongside specific assay cartridges. The platform simplifies the testing process by managing everything from sample and reagent preparation to nucleic acid extraction and amplification, as well as the real-time detection of RNA or DNA target sequences, culminating in either a qualitative or quantitative analysis of the results. This is applicable to a range of sample types. Designed to assist in the precise and rapid diagnosis of related diseases, the Savanna multiplex molecular platform ensures accurate and quick patient diagnoses.

The U.S. Food and Drug Administration has granted QuidelOrtho 510(K) clearance for the Savanna PCR platform, along with its Savanna HSV 1+2/VZV in vitro diagnostic test. This test is specifically designed for the detection and differentiation of Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2), and Varicella-zoster virus (VZV) nucleic acids. These are isolated and purified from swabs taken from cutaneous or mucocutaneous lesion specimens in symptomatic patients. The FDA's clearance enables QuidelOrtho to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay to laboratories in the United States that perform moderate or high complexity diagnostic testing.

“Our relentless pursuit of revolutionizing testing across the healthcare continuum has resulted in the achievement of another major milestone – the clearance of our Savanna platform and the Savanna HSV 1+2/VZV assay,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. “We’re truly differentiating diagnostics in the marketplace and allowing labs and healthcare workers to provide the quick diagnoses needed in critical situations.”

“The Savanna platform’s small footprint hides a powerful set of features, such as integrated sample prep combined with rapid real-time PCR amplification and detection technologies, making it a perfect fit for syndromic testing in hospitals and moderate-complexity labs, with the goal of eventually accessing physician offices, urgent care clinics and other point-of-care locations. Savanna is a truly compelling product, our next flagship platform and an important growth driver,” added Bryant.

Related Links:
QuidelOrtho Corporation 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Whole Blood Control
Lyphochek Whole Blood Control
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.